Jehan Alladina, MD, and colleagues of the Division of Pulmonary and Critical Care Medicine at Massachusetts General Hospital, are using an innovative in vivo research method to study allergic asthma pathogenesis.
Jehan W. Alladina, MD, and Benjamin D. Medoff, MD, of the Division of Pulmonary and Critical Care Medicine, and colleagues advise that high plasma concentrations of soluble suppression of tumorigenicity-2 may signify persistent lung injury in COVID-19 respiratory failure and the need for continued ventilatory support.
Jehan Alladina, MD, and Ednan K. Bajwa, MD, of the Division of Pulmonary and Critical Care Medicine, found that serial measurement of soluble suppression of tumerogenicity-2, an inflammatory biomarker, indicates readiness for ventilator liberation better than standard physiologic measures in patients with acute hypoxemic respiratory failure.
Massachusetts General Hospital researchers find that patients with COVID-19 respiratory failure exhibited gas exchange, respiratory system mechanics and response to prone ventilation similar to that of prior large cohorts of patients with ARDS.
In patients with acute respiratory distress syndrome related to COVID-19, care must be taken to choose the positive end-expiratory pressure that opens alveoli without over-distending the large amount of normal lung.